Guidance and quality standards awaiting development | Guidance

Showing 141 to 150 of 381

Guidance and quality standards awaiting development
Title	Type
GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]	Technology appraisal guidance
Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208]	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [GID-TA12010]	Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance
Iberdomide with dexamethasone and daratumumab for treating relapsed or refractory multiple myeloma after 1 or 2 lines of treatment [TSID12415]	Technology appraisal guidance
ID6611 Obesity, overweight - semaglutide (including review of TA875)	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance